Avalo Therapeutics’ phase 2 trial of abdakibart in hidradenitis suppurativa met the study’s primary endpoint, propelling the company toward registrational work. In a randomized trial of 253 adults with moderate-to-severe HS, HiSCR75 response rates in both abdakibart dosing regimens were about 42% at Week 16, while placebo-subtracted results landed at 16.9%.